Clinical Trials News,

Arrowhead Pharmaceuticals Receives Fast Track Designation for ARO-AAT for Treatment of Alpha-1 Liver Disease

PASADENA, Calif.--(BUSINESS WIRE)--<a href="https://twitter.com/search?q=%24arwr&src=ctag" target="_blank">$arwr</a>--Arrowhead granted Fast Track designation for ARO-AAT, being developed to treat a rare genetic liver disease associated with alpha-1 antitrypsin

Business Wire Health: Clinical Trials News

14:30

LifeMax Receives Orphan Drug Designation From the United States Food & Drug Administration For LM-030 For The Treatment of Netherton Syndrome

PALO ALTO, Calif.--(BUSINESS WIRE)--FDA grants orphan drug designation to LifeMax's LM-030, an investigational therapy licensed from Novartis for the treatment of Netherton Syndrome.

Business Wire Health: Clinical Trials News

14:00